Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

900 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A single-cell atlas of CD19 chimeric antigen receptor T cells.
Li X, Henderson J, Gordon MJ, Sheikh I, Nastoupil LJ, Westin J, Flowers C, Ahmed S, Wang L, Neelapu SS, Strati P, Deng Q, Green MR. Li X, et al. Among authors: green mr. Cancer Cell. 2023 Nov 13;41(11):1835-1837. doi: 10.1016/j.ccell.2023.08.015. Epub 2023 Sep 21. Cancer Cell. 2023. PMID: 37738975 Free article.
Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease.
Dang M, Wang R, Lee HC, Patel KK, Becnel MR, Han G, Thomas SK, Hao D, Chu Y, Weber DM, Lin P, Lutter-Berka Z, Berrios Nolasco DA, Huang M, Bansal H, Song X, Zhang J, Futreal A, Moreno Rueda LY, Symer DE, Green MR, Rojas Hernandez CM, Kroll M, Afshar-Khargan V, Ndacayisaba LJ, Kuhn P, Neelapu SS, Orlowski RZ, Wang L, Manasanch EE. Dang M, et al. Among authors: green mr. Cancer Cell. 2023 Jun 12;41(6):1032-1047.e4. doi: 10.1016/j.ccell.2023.05.007. Cancer Cell. 2023. PMID: 37311413 Free PMC article.
A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma.
Strati P, Jallouk A, Deng Q, Li X, Feng L, Sun R, Adkins S, Johncy S, Cain T, Steiner RE, Ahmed S, Chihara D, Fayad LE, Iyer SP, Horowitz S, Nastoupil LJ, Nair R, Hassan A, Daoud TE, Hawkins M, Rodriguez MA, Shpall EJ, Ramdial JL, Kebriaei P, Hong DS, Westin JR, Neelapu SS, Green MR. Strati P, et al. Among authors: green mr. Blood Adv. 2023 Nov 14;7(21):6785-6789. doi: 10.1182/bloodadvances.2023010653. Blood Adv. 2023. PMID: 37389847 Free PMC article. Clinical Trial. No abstract available.
Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study.
Gordon MJ, Feng L, Strati P, Lee HJ, Hagemeister FB, Westin JR, Samaniego F, Marques-Piubelli ML, Vega Vazquez F, Parra Cuentas ER, Solis-Soto LM, Ma W, Wang J, Claret L, Averill B, Ibanez K, Fayad LE, Flowers CR, Green MR, Davis RE, Neelapu SS, Fowler NH, Nastoupil LJ. Gordon MJ, et al. Among authors: green mr. Cancer. 2024 Mar 15;130(6):876-885. doi: 10.1002/cncr.35114. Epub 2023 Nov 20. Cancer. 2024. PMID: 37985359 Clinical Trial.
SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions.
Deng Q, Lakra P, Gou P, Yang H, Meydan C, Teater M, Chin C, Zhang W, Dinh T, Hussein U, Li X, Rojas E, Liu W, Reville PK, Kizhakeyil A, Barisic D, Parsons S, Wilson A, Henderson J, Scull B, Gurumurthy C, Vega F, Chadburn A, Cuglievan B, El-Mallawany NK, Allen C, Mason C, Melnick A, Green MR. Deng Q, et al. Among authors: green mr. Cancer Cell. 2024 Apr 8;42(4):605-622.e11. doi: 10.1016/j.ccell.2024.02.011. Epub 2024 Mar 7. Cancer Cell. 2024. PMID: 38458188 Free article.
Activated B cells suppress T-cell function through metabolic competition.
Imahashi N, Basar R, Huang Y, Wang F, Baran N, Banerjee PP, Lu J, Nunez Cortes AK, Uprety N, Ensley E, Muniz-Feliciano L, Laskowski TJ, Moyes JS, Daher M, Mendt M, Kerbauy LN, Shanley M, Li L, Lim FLWI, Shaim H, Li Y, Konopleva M, Green M, Wargo J, Shpall EJ, Chen K, Rezvani K. Imahashi N, et al. J Immunother Cancer. 2022 Dec;10(12):e005644. doi: 10.1136/jitc-2022-005644. J Immunother Cancer. 2022. PMID: 36543374 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 39112364
CREBBP histone acetyltransferase domain mutations predict response to mTOR inhibition in relapsed/refractory follicular lymphoma.
Kumar EA, Korfi K, Bewicke-Copley F, Close K, Heward J, Witzig T, Leukam M, Ansell S, Scott J, Clear A, Efeyan A, Green M, Siebert R, Peck B, Calaminici M, Wang J, Smith S, Novak A, Fitzgibbon J, Okosun J. Kumar EA, et al. Br J Haematol. 2024 Nov;205(5):1804-1809. doi: 10.1111/bjh.19671. Epub 2024 Aug 26. Br J Haematol. 2024. PMID: 39188028
Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphoma.
MacManus MP, Seymour JF, Tsang H, Fisher R, Keane C, Sabdia MB, Law SC, Gunawardana J, Nath K, Kazakoff SH, Marques-Piubelli ML, Duenas DE, Green MR, Roos D, O'Brien P, McCann A, Tsang R, Davis S, Christie D, Cheah C, Amanuel B, Cochrane T, Butler J, Johnston A, Shanavas M, Li L, Vajdic C, Kridel R, Shelton V, Hershenfield S, Baetz T, Lebrun D, Johnson N, Brodtkorb M, Ludvigsen M, d'Amore F, Thompson ER, Blombery P, Gandhi MK, Tobin JWD. MacManus MP, et al. Among authors: green mr. EBioMedicine. 2024 Dec;110:105468. doi: 10.1016/j.ebiom.2024.105468. Epub 2024 Dec 3. EBioMedicine. 2024. PMID: 39631145 Free PMC article. Clinical Trial.
900 results